CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has announced it will release its Q3 2024 financial results on November 14, 2024, before market open.

Rhea-AI Summary

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has announced it will release its Q3 2024 financial results on November 14, 2024, before market open. The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. The webcast will be available on the company's Investor Relations website and archived for approximately 30 days. U.S. investors can join via (877) 407-0784, while international callers can use (201) 689-8560. A replay will be available until November 21, 2024.

Argus Session date unavailable

+1.72% session move Open Argus

Details

News Market Reaction – CVSI

The recorded move for CVSI in the trading session of this news was +1.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2024, before the stock market opens on Thursday, November 14, 2024. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.

The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1695466&tp_key=e08c31edf2. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560.  Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.

A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 21, 2024, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13749925.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foods™ brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com. 

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.

CONTACT INFORMATION:
ir@cvsciences.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cv-sciences-inc-to-announce-third-quarter-2024-results-on-november-14-2024-302299782.html

SOURCE CV Sciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CV Sciences (CVSI) release Q3 2024 earnings?

CV Sciences will release Q3 2024 earnings on Thursday, November 14, 2024, before the stock market opens.

What time is CV Sciences (CVSI) Q3 2024 earnings call?

The earnings call is scheduled for 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on November 14, 2024.

How can investors access CV Sciences (CVSI) Q3 2024 earnings call?

Investors can join via webcast at the company's IR website, or dial (877) 407-0784 (US) or (201) 689-8560 (international).

How long will CV Sciences (CVSI) Q3 2024 earnings call replay be available?

The earnings call replay will be available until November 21, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international).